Nothing Special   »   [go: up one dir, main page]

PT3389699T - Anticorpos monoclonais quiméricos e humanizados anti-ctla4 humano e utilizações dos mesmos - Google Patents

Anticorpos monoclonais quiméricos e humanizados anti-ctla4 humano e utilizações dos mesmos

Info

Publication number
PT3389699T
PT3389699T PT168766129T PT16876612T PT3389699T PT 3389699 T PT3389699 T PT 3389699T PT 168766129 T PT168766129 T PT 168766129T PT 16876612 T PT16876612 T PT 16876612T PT 3389699 T PT3389699 T PT 3389699T
Authority
PT
Portugal
Prior art keywords
chimeric
monoclonal antibodies
humanized anti
human ctla4
ctla4 monoclonal
Prior art date
Application number
PT168766129T
Other languages
English (en)
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Publication of PT3389699T publication Critical patent/PT3389699T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT168766129T 2015-12-15 2016-12-14 Anticorpos monoclonais quiméricos e humanizados anti-ctla4 humano e utilizações dos mesmos PT3389699T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US201662359036P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
PT3389699T true PT3389699T (pt) 2024-06-04

Family

ID=59057509

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168766129T PT3389699T (pt) 2015-12-15 2016-12-14 Anticorpos monoclonais quiméricos e humanizados anti-ctla4 humano e utilizações dos mesmos

Country Status (25)

Country Link
US (3) US10618960B2 (pt)
EP (2) EP4374926A3 (pt)
JP (4) JP6858779B2 (pt)
KR (1) KR20180086219A (pt)
CN (2) CN108430499B (pt)
AU (2) AU2016370648B2 (pt)
BR (1) BR112018012113A2 (pt)
CA (1) CA3006984C (pt)
DK (1) DK3389699T5 (pt)
ES (1) ES2979210T3 (pt)
FI (1) FI3389699T3 (pt)
HR (1) HRP20240719T1 (pt)
HU (1) HUE066907T2 (pt)
IL (3) IL296354B2 (pt)
LT (1) LT3389699T (pt)
MX (1) MX2018006925A (pt)
MY (1) MY186974A (pt)
PL (1) PL3389699T3 (pt)
PT (1) PT3389699T (pt)
RS (1) RS65703B1 (pt)
SG (1) SG11201804969PA (pt)
SI (1) SI3389699T1 (pt)
TW (1) TWI739781B (pt)
WO (1) WO2017106372A1 (pt)
ZA (1) ZA201804077B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
KR102504605B1 (ko) 2016-12-07 2023-03-02 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
JP2021502100A (ja) * 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
WO2019152413A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
US12129299B2 (en) 2018-02-02 2024-10-29 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP3802613A4 (en) * 2018-06-05 2022-03-09 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. DIMERE AND ITS USE
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
AU2019413366A1 (en) * 2018-12-27 2021-08-12 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
WO2021208838A1 (en) * 2020-04-13 2021-10-21 Biosion Inc. Antibodies binding ctla4 and uses thereof
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
KR20220112208A (ko) * 2021-02-03 2022-08-10 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP2024515263A (ja) 2021-04-09 2024-04-08 オーエスイー・イミュノセラピューティクス 改善された特性を有する二機能性分子のための新規足場構造
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
AU2022361768A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022359021A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024059833A1 (en) 2022-09-16 2024-03-21 OncoC4, Inc. Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024227176A1 (en) 2023-04-28 2024-10-31 OncoC4, Inc. Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
ATE353365T1 (de) 1999-08-23 2007-02-15 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2006029220A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Combination therapy with anti-ctla4 and anti-4-1bb antibodies
AU2005295579B2 (en) 2004-10-15 2011-08-04 NortonLifeLock Inc. One time password
SG158919A1 (en) * 2005-01-24 2010-02-26 Univ Texas Constructs binding to phosphatidylserine and their use in disease treatment
CA3151350A1 (en) * 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
SI2925350T1 (sl) * 2012-12-03 2019-04-30 Bristol-Myers Squibb Company Izboljšanje protirakave aktivnosti imunomodulatornih FC fuzijskih proteinov
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用

Also Published As

Publication number Publication date
IL296354B2 (en) 2024-07-01
WO2017106372A1 (en) 2017-06-22
MX2018006925A (es) 2018-08-01
IL259988B (en) 2022-10-01
EP3389699A1 (en) 2018-10-24
MY186974A (en) 2021-08-26
JP7286845B2 (ja) 2023-06-05
SG11201804969PA (en) 2018-07-30
HRP20240719T1 (hr) 2024-09-13
US20230391870A1 (en) 2023-12-07
JP6858779B2 (ja) 2021-04-14
IL259988A (en) 2018-07-31
CN116063492A (zh) 2023-05-05
CN108430499B (zh) 2022-07-19
CA3006984A1 (en) 2017-06-22
AU2016370648B2 (en) 2023-03-09
BR112018012113A2 (pt) 2018-12-04
IL296354B1 (en) 2024-03-01
EP3389699B1 (en) 2024-05-01
SI3389699T1 (sl) 2024-07-31
KR20180086219A (ko) 2018-07-30
US20200283526A1 (en) 2020-09-10
JP2021100957A (ja) 2021-07-08
LT3389699T (lt) 2024-06-10
JP2019510733A (ja) 2019-04-18
EP3389699A4 (en) 2019-07-10
US10618960B2 (en) 2020-04-14
CA3006984C (en) 2023-10-17
US11629188B2 (en) 2023-04-18
JP2023106547A (ja) 2023-08-01
ZA201804077B (en) 2019-09-25
EP4374926A3 (en) 2024-08-07
FI3389699T3 (fi) 2024-05-28
CN108430499A (zh) 2018-08-21
ES2979210T3 (es) 2024-09-24
DK3389699T3 (da) 2024-05-13
TWI739781B (zh) 2021-09-21
IL296354A (en) 2022-11-01
EP4374926A2 (en) 2024-05-29
AU2016370648A1 (en) 2018-06-21
PL3389699T3 (pl) 2024-07-22
IL310404A (en) 2024-03-01
US20190127468A1 (en) 2019-05-02
IL259988B2 (en) 2023-02-01
AU2023203169A1 (en) 2023-06-15
HUE066907T2 (hu) 2024-09-28
DK3389699T5 (da) 2024-09-23
TW201731877A (zh) 2017-09-16
JP2022123049A (ja) 2022-08-23
RS65703B1 (sr) 2024-07-31

Similar Documents

Publication Publication Date Title
ZA201804077B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
IL311371A (en) CD3 antibodies of human origin or chimeras
IL256562A (en) Human cd3 antibodies or chimeras
HK1223943A1 (zh) 嵌合的靶向抗原受體的單克隆抗體
EP3286223B8 (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
EP3459973A4 (en) HUMANIZED MONOCLONAL ANTI-HUMAN PD-L1 ANTIBODY AND APPLICATION THEREOF
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
EP3466974A4 (en) HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-1 ANTIBODIES AND ITS USE
IL262776A (en) Human anti-il-1r3 antibodies
IL263936A (en) Humanized monoclonal antibodies targeting hptp-beta)ve-ptp)
IL282756A (en) Humanized antibodies against SIRPα
EP3131917A4 (en) Humanized and chimeric monoclonal antibodies to cd99
EP3471762A4 (en) HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES DIRECTED AGAINST CD81
HK1255635A1 (zh) 人源化或嵌合的cd3抗體